Crossject provides strategic update on priorities for 2024
Focusing on regulatory filings and accelerating U.S. commercialization efforts
- Focusing on regulatory filings and accelerating U.S. commercialization efforts
Contract of up to $155 million with BARDA for U.S. stockpiling continues to advance
Dijon, France February 6, 2024 –530 pm CET Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, provides a summary of recent milestones reached and an update on its strategic priorities for 2024. - Syneos Health has a strong U.S. presence and significant expertise in commercializing new therapies for Crossject, as it approaches filing for regulatory approval.
- In 2024, Crossject will especially focus on regulatory approvals for ZEPIZURE® and accelerating market access efforts in the United States.
- We are working closely with our strategic partners market access activities in the US,” said Patrick Alexandre, CEO of Crossject.